AlloVir Company
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.
Technology:
COVID, Cell-based gene therapy
Industry:
Altered Signaling, Public
Headquarters:
Houston, Texas, United States
Founded Date:
2013-01-01
Employees Number:
101-250
Funding Status:
IPO
Investors Number:
12
Total Funding:
285590000
Estimated Revenue:
$1M to $10M
Last Funding Date:
2022-07-27
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership